Agalsidase alfa: enzyme therapy for Anderson––Fabry disease

Author： Pastores G M  

Publisher： Future Medicine

ISSN： 1475-0708

Source： Therapy, Vol.1, Iss.2, 2004-11, pp. : 203-211

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gender‐specific plasma proteomic biomarkers in patients with Anderson–Fabry disease

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 3, 2015-03 ,pp. : 291-300

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy

By  

ACTA OPHTHALMOLOGICA, Vol. 96, Iss. 2, 2018-03 ,pp. : e255-e256

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phenotype and Genotype Characterization and Twin Association in Patients with Anderson-Fabry Cardiomyopathy

By  

Cardiology, Vol. 121, Iss. 2, 2012-03 ,pp. : 71-75

Karger

Access to resources Recommend Favorite

Velaglucerase alfa (VPRIV) enzyme replacement therapy in patients with Gaucher disease: Long‐term data from phase III clinical trials

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 584-591

John Wiley & Sons Inc

Access to resources Recommend Favorite

Thrombocytosis Associated with Enzyme Replacement Therapy in Gaucher Disease

By  

Acta Haematologica, Vol. 108, Iss. 2, 2002-08 ,pp. : 94-96

Karger

Access to resources Recommend Favorite